Chelidonium majus - An integrative review: Traditional knowledge versus modern findings

Forschende Komplementarmedizin

Volumn 17, Issue 5, 2010, Pages 241-248

  Gilca, Marilena ^a,b   Gaman, Laura ^a,b   Panait, Elena ^a   Stoian, Irina ^a,b   Atanasiu, Valeriu ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b R and D IRIST LABMED SRL   (Romania)

Author keywords

Chelidonium majus; Chinese medicine; Greater celandine; Integrative medicine; Medicinal plant; Phytotherapy

Indexed keywords

ALKALOID; FLAVONOID; PHENOL DERIVATIVE; PLANT MEDICINAL PRODUCT;

ANIMAL; CELLULAR IMMUNITY; CHELIDONIUM; CHEMISTRY; CHILD; DRUG EFFECT; HUMAN; HUMORAL IMMUNITY; METHODOLOGY; MOUSE; PHYTOTHERAPY; RAT; REVIEW; TONSILLITIS;

ALKALOIDS; ANIMALS; CHELIDONIUM; CHILD; FLAVONOIDS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; PHENOLS; PHYTOTHERAPY; PLANT PREPARATIONS; RATS; TONSILLITIS;

EID: 78049506966     PISSN: 16614119     EISSN: 16614127     Source Type: Journal    
DOI: 10.1159/000321397     Document Type: Article

References (71)

1. Colombo ML, Bosisio E: Pharmacological activities of Chelidonium majus L. (Papaveraceae). Pharmacol Res 1996;33(2):127-34.
2. Culpeper N: Culpeper's Complete Herbal. A Book of Natural Remedies for Ancient Ills. Hertfordshire, Wordsworth, 1995.
3. Mills S, Bone K, Corrigan D, Duke JA, Wright JV: Principles and practice of phytotherapy: modern herbal medicine. Edinburgh, Churchill Livingstone, 2008.
4. Thornton RJ: A New Family Herbal: or, Popular Account of the Natures and Properties of the Various Plants Used in Medicine, Diet, and the Arts. London, Philipps, 1810.
5. Stephenson J, Churchill JM, Burnett GT: Medical Botany; or, Illustrations and Descriptions of the Medicinal Plants. London, Medical Bookseller and Publisher, 1864.
6. Huang CK: The Pharmacology of Chinese Herbs, ed 2. Boca Raton, FL, CRC, 1999.
7. Tierra M: Planetary Herbology: An Integration of Western Herbs into the Traditional Chinese and Ayurvedic Systems. Sante FE, NM, Lotus), 1992, pp 209-210.
8. Jeng JH, Wu HL, Lin BR, Lan WH, Chang HH, Ho YS, Lee PH, Wang YJ, Wang JS, Chen YJ, Chang MC: Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thrombox-ane and cAMP production. Atherosclerosis 2007; 191(2):250-258.
9. Saeed SA, Gilani AH, Amjoo RU, Shah BH: An-tithrombotic and anti-inflammatory activities of protopine. Pharmacol Res 1997;37:1-7.
10. Lee YC, Kim SH, Roh SS, Choi HY, Seo YB: Suppressive effects of Chelidonium majus metha-nol extract in knee joint, regional lymph nodes, and spleen on collagen-induced arthritis in mice. J Eth-nopharmacol 2007;112(1):40-48.
11. Kokoska L, Polensky Z, Rada V, Nepovim A, Vanek T: Screening of some Siberian medicinal plants for antimicrobial activity. J Ethnopharmacol 2002;82(1):51-53.
12. Zuo GY, Meng FY, Hao XY, Zhang YL, Wang GC, Xu GL: Antibacterial alkaloids from Cheli-donium majus Linn (Papaveraceae) against clinical isolated of methicillin-resistant Staphylococcus aureus. J Pharm Pharm Sci 2008;11(4):90-94.
13. Cheng RB, Chen X, Liu SJ, Zhang XF: [Effect of Chelerythrine on cell surface hydrophobicity and adherence of Streptococcus mutans.] Shanghai Kou Qiang Yi Xue 2007;16(1):68-72.
14. Cheng RB, Chen X, Liu SJ, Zhang XF, Zhang GH: [Experimental study of the inhibitory effects of Chelidonium majus L. extractive on Streptococcus mutans in vitro.] Shanghai Kou Qiang Yi Xue 2006;15(3):318-320.
15. Fik E, Gozdzicka-Jozefiak A, Haertle T, Mirska I, Kedzia W: New plant glycoprotein against methi-cillin resistant staphylococci and enterococci. Acta Microbiol Pol 1997;46(3):325-327.
16. Fik E, Wołuï-Cholewa M, Kistowska M, Warchoł JB, Goêdzicka-Józefiak A: Effect of lectin from Chelidonium majus L. on normal and cancer cells in culture. Folia Histochem Cytobiol 2001;39(2): 215-216.
17. Garcia VP, Valdes F, Martin R, Luis JC, Alfonso AM, Ayala JH: Biosynthesis of antitumoral and bactericidal sanguinarine. J Biomed Biotechnol 2006; doi:10.1155/JBB/2006/63518.
18. Dzink JL, Socransky SS: Comparative in vitro activity of sanguinarine against oral microbial isolates. Antimicrob Agents Chemother 1985;27(4): 663-665.
19. Bark KM, Heo EP, Han KD, Kim MB, Lee ST, Gil EM, Kim TH: Evaluation of the phototoxic potential of plants used in oriental medicine. J Ethnopharmacol 2010;127(1):11-18.
20. Matos OC, Baeta J, Silva MJ, Pinto Ricardo C: Sensitivity of Fusarium starins to Chelidonium majus L. extracts. J Ethnopharmacol 1999;66(2): 151-158.
21. Parvu M, Parvu AE, Cranium C, Barbu-Tudoran L, Tamas M: Antifungal activities of Chelidonium majus extract on Botrytis cinerea in vitro and ultrastructural changes in its conidia. J Phytopat 2008;156(9):550-552.
22. Meng F, Zuo G, Hao X, Wang G, Xiao H, Zhang J, Xu G: Antifungal activity of the benzo[c]phen-anthridine alkaloids from Chelidonium majus Linn against resistant clinical yeast isolates. J Ehnophar-macol 2009;125(3):494-496.
23. Gerencer M, Turecek PL, Kistner O, Mitterer A, Savidis-Dacho H, Barrett NP: In vitro and in vivo anti-retroviral activity of the substance purified from the aqueous extract of Chelidonium majus L. Antiviral Res 2006;72(2):153-156.
24. Lozjuk RM, Lisnyak OI, Lozjuk LV: Theoretical grounds and experimental confirmation of the antiviral effect of the preparation Ukrain. Drugs Exp Clin Res 1996;22(3-5):213-217.
25. Song JY, Yang HO, Pyo SN, Jung IS, Yi SY, Yun YS: Immunomodulatory activity of protein-bound polysaccharide extracted from Chelidonium majus. Arch Pharm Res 2002;25(2):158-164.
26. Chung HS, An HJ, Jeong HJ, Won JH, Hong SH, Kim HM: Water extract isolated from Cheli-donium majus enhances nitric oxide and tumour necrosis factor-alpha production via nuclear factor-kappa B activation in mouse peritoneal macro-phages. J Pharm Pharmacol 2004;56(1):129-34.
27. Khmel'nitskaia Nm, Vorob'ev KV, Kliachko LL, Ankhimova ES, Kosenko VA, Tymova EV, Mal'seva GS, Medvedev EA: A comparative study of conservative treatment schemes in chronic tonsillitis in children. Vestn otorinolaringol 1998;4:39-42.
28. Ni Maoshing: The Yellow Emperor's Classic of Medicine. A New Translation of the Neijing Suwen with Commentary. London, Shambala, 1995.
29. Khayyal MT, el-Ghazaly MA, Kenawy SA, Seif-el-Nasr M, Mahran LG, Kafafi YA, Okpanyi SN: Antiulcerogenic effect of some gastrointesti-nally acting plant extracts and their combination. Arznei mittelforschung 2001;51(7):545-553.
30. Vahlensieck U, Hahn R, Winterhoff H, Gumbin-ger HG, Nahrstedt A, Kemper FH: The effect of Chelidonium majus herb extract on choleresis in the isolated perfused rat liver. Planta Med 1995; 61:267-271.
31. Baumann JC: Über die Wirkung von Chelido-nium, Curcuma, Absinth und Carduus marianus auf die Galle-und Pankreassekretion bei Hepat-opathien. Med Monatsschr 1975;29:173-180.
32. Baumann JC, Heintze K, Muth HW: Klinisch-experimentelle Untersuchungen der Gallen-, Pancreas-und Magensaftsekretion unter den phy-tocolagogen Wirkstoffen einer Carduus marianus-Chelidonium-Curcuma-Suspension. Arzneimittel-forschung/Drug Res 1971;21:98-101.
33. ESCOP (European Scientific Cooperative on Phy-totherapy) Monographs: The Scientific Foundation for Herbal Medicinal Products, ed 2. Exeter, Ar-gyle, 2003, pp 74-78.
34. Von Zerssen D: Die Beschwerden-Liste. Manual. Weinheim, Beltz Test, 1976.
35. Ardjah H: Therapeutische Aspekte der funkio-nellen Oberbauchbeschwerden bei Gallenwegs-erkrankungen. Fortschr Med 1991;109(suppl 115): 2-8.
36. Kniebel R, Urlacher W: Therapie krampfartiger Abdominalschmerzen. Hochdosierter Schollkraut-extrakt bei krampfartigen Abdominalschmerzen. Z Allg Med 1993;69:680-684.
37. Mitra S, Gole M, Samajdar K, Sur RK, Chakra-borty BN: Antihepatotoxic activity of Chelidonium majus. Int J Pharmacognosy 1992;30:125-128.
38. Mitra S, Sur RK, Roy A, Mukherjee AS: Effect of Chelidonium majus L. on experimental hepatic tissue injury. Phytother Res 1996;10:354-356
39. Biswas J, Bhattacharjee N, Khuda-Bukhsh AR: Efficacy of a plant extract (Chelidonium majus L.) in combating induced hepatocarcinogenesis in mice. Food Chem Toxicol 2008;46(5):1474-1487.
40. Noureini SK, Wink M: Transcriptional down regulation of hTERT and senescence induction in HepG2 cells by chelidonine. World J Gastroenterol 2009:15(29):2603-3610.
41. Habermehl D, Kammerer B, Handrick R, Eldh T, Gruber C, Cordes N, Daniel PT, Plasswilm L, Bamberg M, Belka C, Jendrossek V: Proapoptotic activity of Ukrain is based on Chelidonium majus L alkaloids and mediated via a mitochondrial death pathway. BMC Cancer 2006;6:14.
42. Philchenkov A, Kaminsky V, Zavelevich M, Stoika R: Apoptogenic activity of two benzophenanthrid-ine alkaloids form Chelidonium majus L. does not correlate with their DNA damaging effects. Toxi-col in vitro 2008;22(2):287-295.
43. Hohenwarter O, Strutzenberger K, Katinger H, Liepins A, Nowicky JW: Selective inhibition of in vitro cell growth by the antitumor drug Ukrain. Drugs Exp Clin Res 1992;18(suppl):1-4.
44. Cordes N, Plasswilm L, Bamberg M, Rodemann HP: Ukrain, an alkaloid thiophosphoric acid derivative of Chelidonium majus L. protects human fibroblasts but not human tumor cells in vitro against ionizing radiation. Int J Radiat Biol 2002; 78(1):17-27.
45. Kim DJ, Ahn B, Han BS, Tsuda H: Potential preventive effects of Chelidonium majus L. (Papaver-aceae) herb extract on glandular stomach tumor development in rats treated with N-methyl-N'-nitro-N nitrosoguanidine (MNNG) and hypertonic sodium chloride. Cancer Lett 1997;112(2):203-208.
46. Lohninger A, Hamler F: Chelidonium majus L. (Ukrain) in the treatment of cancer patients. Drugs Exp Clin Res 1992;18(suppl):73-77.
47. Gansauge F, Ramadani M, Pressmar J, Gansauge S, Muehling B, Stecker K, Cammerer G: NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial. Langen-becks Arch Surg 2002;386(8):570-574.
48. Ernst E, Schmidt K: Ukrain - a new cancer cure? A systematic review of randomised clinical trials. BMC Cancer 2005;5(1):69.
49. Voltchek IV, Liepins A, Nowicky JW, Brzosko WJ: Potential therapeutic efficacy of Ukrain (NSC 631570) in AIDS patients with Kaposi's sarcoma. Drugs Exp Clin Res 1996;22(3-5):283-286.
50. Lahans T: Integrating Conventional and Chinese Medicine in Cancer Cure: A Clinical Guide. Philadelphia, Churchill Livingstone, 2007.
51. Shin MC, Jang MH, Chang HK, Han SM, Park HJ, Shim I, Lee JS, Kim KA, Kim CJ: Modulation of Chelidonii herba on glycine-activated and glutama-te-activated ion currents in rat periaqueductal gray neurons. Clin Chim Acta 2003;337(1-2):93-101.
52. Kim Y, Shin M, Chung J, Kim E, Koo G, Lee C, Kim C: Modulation of Chelidonii herba on GABA activated chloride current in rat PAG neurons. Am J Chin Med 2001;29(2):265-279.
53. Boegge SC, Kesper S, Verspohl EJ, Nahrstedt A: Reduction of Ach-induced contraction of rat isolated ileum by coptisine, (+)caffeoylmalic acid, Chelidonium majus, and Corydalis lutea extracts. Planta Med 1996;62:173-174.
54. Hiller KO, Ghorbani M, Schilcher H: Antispas-modic and relaxant activity of chelidonine, pro-topine, coptisine, and Chelidonium majus extracts on isolated guinea-pig ileum. Planta Med 1998; 64(8):758-760.
55. Niederau C, Göpfert E: The effect of chelidonium-and turmeric root extract on upper abdominal pain due to functional disorders of the biliary system. Results from a placebo-controlled double-blind study. Med Klin (Munich) 1999;94(8):425-430.
56. Song JY, Yang HO, Shim JY, Ji-Yeon-Ahn, Han YS, Jung IS, Yun YS: Radiation protective effect of an extract from Chelidonium majus. Int J He-matol 2003;78(3):226-232.
57. Luksa-Lichtenthaeler GL, Ladutko EI, Nowicky JW: Radiomodification effects of Ukrain, a cyto-static and immunomodulating drug, on intracel-lular glucocorticoid reception during short-term gamma-irradiation. Drugs Exp Clin Res 2000; 26(5-6):311-315.
58. Jabłoïski M, Gorzelak M, Patyra M, Jagiełło- Wójtowicz E: Intermittent three-month treatment with Ukrain in intact and ovariectomized rats. Part II: Effect on bone mineral density of the femur. Drugs Exp Clin Res 2000;26(5-6):327-331. (Pubitemid 32373365)
59. Jabłoïski M, Korczak W, Gorzelak M, Jagiełło- Wójtowicz E: Intermittent three-month treatment with Ukrain in intact and ovariectomized rats. Part III: Effect on the native electron paramagnetic resonance signal intensity of the femur. Drugs Exp Clin Res 2000;26(5-6):333- 336.
60. Jabłoïski M: Ukrain (NSC-631570) influences on bone status: a review. Drugs Exp Clin Res 2000; 26(5-6):317-320.
61. Then M, Szentmihalyi K, Sarkozi A, Varga IS: Examination on antioxidant activity in the greater celandine (Chelidonium majus L.) extracts by FRAP method. Acta Biol Szeged 2003;47(1-4):115-117.
62. Nadova S, Miadokova E, Alfoldiova L, Kopas-kova M, Hasplova K, Hudecova A, Vaculcikova D, Gregan F, Cipak L: Potential antioxidant activity, cytotoxic and apoptosis-inducing effects of Cheli-donium majus L. extract on leukemia cells. Neuro Endocrinol Lett 2008;29(5):649-652.
63. Mazzanti G, Di Sotto A, Franchitto A, Mammola CL, Mariani P, Mastrangelo S, Menniti-Ippolito F, Vitalone A: Chelidonium majus is not hepatotoxic in wistar rats, in a 4 weeks feeding experiment. J Ethnopharmacol 2009;126(3):518-524.
64. Kaminsky V, Lootsik M, Stoika R: Correlation of the cytotoxic activity of four different alkaloids, from Chelidonium majus (greater celandine), with their DNA intercalating properties and ability to induce breaks in the DNA of NK/Ly murine lym-phoma cells. Cent Eur J Biol 2006;1(1):2-15.
65. Crijns AP, de Smet PA, van den Heuvel M, Schot BW, Haagsma EB: Acute hepatitis after use of a herbal preparation with greater celandine (Che-lidonium majus). Ned Tijdschr Geneeskd 2002; 146(3):100-102.
66. Rifai K, Flemming P, Manns MP, Trautwein C: Severe drug hepatitis caused by Chelidonium. Internist (Berl) 2006;47(7):749-751.
67. Haderman E, van Overbeke L, Ilegems S, Ferrante M: Acute hepatitis induced by greater celandine (Chelidonium majus). Acta Gastroenterol Belg 2008;71(2):281-282.
68. Moro PA, Cassetti F, Giugliano G, Falce MT, Maz-zanti G, Menniti-Ippolito F, Raschetti R, Santuccio C: Hepatitis from greater celandine (Chelidonium majus L.): review of literature and report of a new case. J Ethnopharmacol 2009;124(2):328-332.
69. De Smet PA: Safety concerns about kava not unique. Lancet 2002;360(9342):1336.
70. Anonymous: Chelidonium majus. Statement to advice use under supervision. WHO Pharm Newslett 2003;4:4.
71. Cho KM, Yoo ID, Kim WG: 8-hydroxydihydro-chelerythrine and 8-hydroxydihydrosanguinarine with a potent acetylcholinesterase inhibitory activity from Chelidonium majus L. Biol Pharm Bull 2006;29:2317-2320.